Skip to content
HowShorted

Adamas Pharmaceuticals Inc short interest in 2018

In 2018, Adamas Pharmaceuticals Inc's disclosed short interest ran from 32.55% of shares outstanding on 12 Jan 2018 to 23.52% on 31 Dec 2018, a change of -9.03 percentage points. The year's high was 33.70% on 29 Mar 2018 and its low 23.52% on 31 Dec 2018, averaging 29.49% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.32 days on 14 Sep 2018. Full history: Adamas Pharmaceuticals Inc.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021

Aggregate net short position time series for Adamas Pharmaceuticals Inc in 2018

2018 in figures

Start of year
32.55% (12 Jan 2018)
End of year
23.52% (31 Dec 2018)
Change
-9.03 pp
High
33.70% (29 Mar 2018)
Low
23.52% (31 Dec 2018)
Average
29.49%
Highest days to cover
24.32 (14 Sep 2018)
SEC filings marked
9

Every report in 2018

Adamas Pharmaceuticals Inc short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201832.55%11.21
31 Jan 201832.12%6.60results (8-K)
15 Feb 201830.36%8.59
28 Feb 201831.47%3.1810-K filed, results (8-K)
15 Mar 201831.46%7.39
29 Mar 201833.70%8.14
13 Apr 201832.68%13.29
30 Apr 201830.49%10.31
15 May 201829.81%9.8810-Q filed, results (8-K)
31 May 201829.61%14.19
15 Jun 201831.31%14.93
29 Jun 201830.68%13.74
13 Jul 201830.78%21.25
31 Jul 201830.10%18.55
15 Aug 201829.03%9.2010-Q filed, results (8-K)
31 Aug 201828.85%18.00
14 Sep 201828.77%24.32
28 Sep 201828.04%11.21
15 Oct 201827.04%12.05
31 Oct 201824.74%17.70
15 Nov 201827.15%5.7310-Q filed, results (8-K)
30 Nov 201826.86%16.26
14 Dec 201826.71%14.07
31 Dec 201823.52%7.29

See also: Adamas Pharmaceuticals Inc's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.